Xilio Therapeutics, Inc. (XLO)
NASDAQ: XLO · Real-Time Price · USD
7.48
-0.85 (-10.20%)
May 5, 2026, 3:31 PM EDT - Market open
Company Description
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies.
The company’s pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody.
The company was founded in 2016 and is headquartered in Waltham, Massachusetts.
Xilio Therapeutics, Inc.
| Country | United States |
| Founded | 2016 |
| IPO Date | Oct 22, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 76 |
| CEO | Rene Russo |
Contact Details
Address: 828 Winter Street, Suite 300 Waltham, Massachusetts 02451 United States | |
| Phone | 857 524 2466 |
| Website | xiliotx.com |
Stock Details
| Ticker Symbol | XLO |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 1840233 |
| CUSIP Number | 98422T209 |
| ISIN Number | US98422T2096 |
| Employer ID | 85-1623397 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Rene Russo BCPS, Pharm.D. | President, Chief Executive Officer and Director |
| Christopher Frankenfield | Chief Financial Officer and Chief Operating Officer |
| Dr. Katarina Luptakova M.D. | Chief Medical Officer |
| Kevin M. Brennan | Senior Vice President of Finance and Accounting |
| Dr. Uli Bialucha Ph.D. | Chief Scientific Officer |
| Nathan McBride | Chief Information Officer |
| Caroline Hensley | Chief Legal Officer |
| Dr. Scott Coleman Ph.D. | Chief Development Officer |
| Ruth du Moulin | Senior Vice President of Medical Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 28, 2026 | ARS | Filing |
| Apr 28, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 16, 2026 | 8-K | Current Report |
| Mar 23, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 23, 2026 | 10-K | Annual Report |
| Mar 23, 2026 | 8-K | Current Report |
| Mar 12, 2026 | 8-K | Current Report |
| Mar 9, 2026 | 8-K | Current Report |
| Feb 24, 2026 | 8-K | Current Report |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |